Stan Neil Finkelstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fuzzy Logic | 2 | 2015 | 58 | 0.920 |
Why?
|
Intensive Care Units | 7 | 2021 | 3800 | 0.840 |
Why?
|
Drug Repositioning | 2 | 2022 | 246 | 0.720 |
Why?
|
Absorbable Implants | 1 | 2021 | 337 | 0.640 |
Why?
|
Antihypertensive Agents | 2 | 2022 | 2029 | 0.430 |
Why?
|
Influenza, Human | 3 | 2016 | 1541 | 0.400 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2021 | 1126 | 0.360 |
Why?
|
Commerce | 1 | 2016 | 612 | 0.350 |
Why?
|
Fluid Therapy | 1 | 2013 | 587 | 0.330 |
Why?
|
Career Choice | 1 | 2016 | 769 | 0.330 |
Why?
|
Laboratories | 1 | 2012 | 463 | 0.320 |
Why?
|
Histamine H1 Antagonists | 2 | 1999 | 101 | 0.320 |
Why?
|
Decision Support Systems, Clinical | 2 | 2019 | 1178 | 0.310 |
Why?
|
Triage | 3 | 2020 | 997 | 0.310 |
Why?
|
Blood Transfusion | 4 | 2021 | 1309 | 0.300 |
Why?
|
Efficiency | 8 | 2005 | 479 | 0.300 |
Why?
|
Models, Theoretical | 2 | 2021 | 3573 | 0.300 |
Why?
|
Health Resources | 2 | 2011 | 950 | 0.300 |
Why?
|
Influenza Vaccines | 2 | 2016 | 781 | 0.290 |
Why?
|
Economics, Pharmaceutical | 1 | 2007 | 88 | 0.280 |
Why?
|
Health Benefit Plans, Employee | 2 | 2000 | 332 | 0.270 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 452 | 0.270 |
Why?
|
Artificial Intelligence | 3 | 2021 | 2665 | 0.270 |
Why?
|
Education, Medical, Undergraduate | 1 | 2016 | 1085 | 0.270 |
Why?
|
Pancreatitis | 1 | 2013 | 1087 | 0.270 |
Why?
|
Databases, Factual | 5 | 2022 | 8080 | 0.260 |
Why?
|
Models, Statistical | 3 | 2022 | 5107 | 0.260 |
Why?
|
Drug Costs | 7 | 2004 | 1195 | 0.250 |
Why?
|
Disaster Planning | 1 | 2011 | 560 | 0.250 |
Why?
|
Cost of Illness | 7 | 2005 | 1951 | 0.250 |
Why?
|
Home Care Services | 1 | 2011 | 659 | 0.240 |
Why?
|
Patient Admission | 4 | 2020 | 1365 | 0.230 |
Why?
|
Primary Prevention | 1 | 2011 | 1188 | 0.230 |
Why?
|
Anemia | 3 | 2005 | 1514 | 0.220 |
Why?
|
Decision Support Techniques | 1 | 2013 | 2008 | 0.210 |
Why?
|
Disease Outbreaks | 2 | 2017 | 1761 | 0.200 |
Why?
|
Students, Medical | 1 | 2016 | 1964 | 0.200 |
Why?
|
Ventricular Function, Left | 1 | 2015 | 3941 | 0.200 |
Why?
|
Antidepressive Agents | 4 | 2004 | 2913 | 0.200 |
Why?
|
Health Expenditures | 4 | 2005 | 2389 | 0.200 |
Why?
|
Pneumonia | 1 | 2013 | 2163 | 0.190 |
Why?
|
Computer Simulation | 2 | 2022 | 6283 | 0.190 |
Why?
|
Stroke Volume | 1 | 2015 | 5622 | 0.190 |
Why?
|
Drug Industry | 2 | 2007 | 791 | 0.180 |
Why?
|
Erythropoietin | 3 | 2005 | 718 | 0.180 |
Why?
|
Achilles Tendon | 1 | 2022 | 181 | 0.170 |
Why?
|
Work Capacity Evaluation | 1 | 1999 | 42 | 0.170 |
Why?
|
Systems Analysis | 1 | 2020 | 168 | 0.160 |
Why?
|
Bayes Theorem | 1 | 2007 | 2359 | 0.160 |
Why?
|
Causality | 2 | 2022 | 1254 | 0.160 |
Why?
|
Tendon Injuries | 1 | 2022 | 329 | 0.160 |
Why?
|
Sickness Impact Profile | 1 | 1999 | 299 | 0.150 |
Why?
|
Public Health | 1 | 2011 | 2679 | 0.150 |
Why?
|
Anterior Cruciate Ligament | 1 | 2021 | 423 | 0.150 |
Why?
|
Respiratory Hypersensitivity | 1 | 1999 | 272 | 0.150 |
Why?
|
Bone Screws | 1 | 2021 | 534 | 0.150 |
Why?
|
Blood Glucose | 3 | 2021 | 6430 | 0.140 |
Why?
|
Biotechnology | 1 | 2019 | 283 | 0.140 |
Why?
|
Imipramine | 2 | 2000 | 98 | 0.140 |
Why?
|
1-Naphthylamine | 1 | 1996 | 48 | 0.130 |
Why?
|
Insulin | 2 | 2021 | 6607 | 0.130 |
Why?
|
Costs and Cost Analysis | 4 | 2018 | 1667 | 0.130 |
Why?
|
Forecasting | 2 | 2020 | 2945 | 0.130 |
Why?
|
Antineoplastic Agents | 5 | 2007 | 13676 | 0.120 |
Why?
|
Sleep Stages | 1 | 1999 | 706 | 0.120 |
Why?
|
Metformin | 1 | 2022 | 909 | 0.120 |
Why?
|
Drug Utilization | 4 | 2004 | 1189 | 0.120 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2007 | 330 | 0.120 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2019 | 3447 | 0.120 |
Why?
|
Islets of Langerhans Transplantation | 1 | 2019 | 748 | 0.110 |
Why?
|
Depressive Disorder | 5 | 2002 | 3721 | 0.110 |
Why?
|
Electronic Health Records | 2 | 2022 | 4887 | 0.110 |
Why?
|
ROC Curve | 3 | 2021 | 3628 | 0.110 |
Why?
|
Acid-Base Imbalance | 1 | 2013 | 41 | 0.110 |
Why?
|
Humans | 57 | 2022 | 768166 | 0.110 |
Why?
|
Health Services Accessibility | 1 | 2011 | 5520 | 0.100 |
Why?
|
Hypoglycemia | 1 | 2020 | 895 | 0.100 |
Why?
|
United States | 24 | 2020 | 73039 | 0.100 |
Why?
|
Insulin-Secreting Cells | 1 | 2019 | 899 | 0.100 |
Why?
|
Cyclohexanols | 2 | 2002 | 126 | 0.100 |
Why?
|
Medical Errors | 1 | 2020 | 1260 | 0.100 |
Why?
|
Absenteeism | 5 | 2000 | 247 | 0.100 |
Why?
|
Employee Performance Appraisal | 2 | 2005 | 86 | 0.100 |
Why?
|
Deductibles and Coinsurance | 2 | 2004 | 315 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2020 | 1388 | 0.090 |
Why?
|
Home Nursing | 1 | 2011 | 92 | 0.090 |
Why?
|
Hypoglycemic Agents | 2 | 2022 | 3109 | 0.090 |
Why?
|
Drug Prescriptions | 3 | 2006 | 1668 | 0.090 |
Why?
|
Health Promotion | 1 | 2003 | 2210 | 0.090 |
Why?
|
Heart Failure | 1 | 2015 | 11879 | 0.090 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2012 | 252 | 0.090 |
Why?
|
Platelet Count | 1 | 2013 | 787 | 0.090 |
Why?
|
Portugal | 2 | 2020 | 91 | 0.090 |
Why?
|
Cost-Benefit Analysis | 7 | 2022 | 5536 | 0.080 |
Why?
|
Vasoconstrictor Agents | 1 | 2013 | 656 | 0.080 |
Why?
|
Leukocyte Count | 1 | 2013 | 1609 | 0.080 |
Why?
|
Depression | 3 | 2004 | 8230 | 0.080 |
Why?
|
Lactic Acid | 1 | 2013 | 1140 | 0.070 |
Why?
|
Cross Infection | 1 | 2017 | 1426 | 0.070 |
Why?
|
Dementia | 1 | 2022 | 2740 | 0.070 |
Why?
|
Hospitals | 2 | 2020 | 3886 | 0.070 |
Why?
|
Retrospective Studies | 13 | 2020 | 81762 | 0.070 |
Why?
|
Critical Illness | 1 | 2020 | 2756 | 0.070 |
Why?
|
Health Care Costs | 5 | 2002 | 3239 | 0.070 |
Why?
|
Culture Media | 2 | 2019 | 898 | 0.070 |
Why?
|
Family Health | 1 | 2011 | 1255 | 0.070 |
Why?
|
Students | 1 | 2016 | 1744 | 0.070 |
Why?
|
Drug Labeling | 2 | 2006 | 250 | 0.070 |
Why?
|
Respiration | 1 | 2012 | 1665 | 0.060 |
Why?
|
Risk Assessment | 4 | 2020 | 24315 | 0.060 |
Why?
|
Temperature | 1 | 2012 | 2234 | 0.060 |
Why?
|
Hepatitis | 2 | 1979 | 227 | 0.060 |
Why?
|
Emergency Service, Hospital | 3 | 2020 | 7951 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10399 | 0.060 |
Why?
|
Male | 26 | 2021 | 364719 | 0.060 |
Why?
|
Blood Donors | 2 | 1979 | 343 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1798 | 0.060 |
Why?
|
Female | 27 | 2021 | 397192 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2012 | 14729 | 0.060 |
Why?
|
Hemodynamics | 1 | 2015 | 4194 | 0.060 |
Why?
|
Severity of Illness Index | 4 | 2015 | 15948 | 0.060 |
Why?
|
Health Maintenance Organizations | 2 | 2004 | 657 | 0.060 |
Why?
|
Vaccination | 1 | 2016 | 3437 | 0.060 |
Why?
|
Neoplasms | 5 | 2007 | 22371 | 0.060 |
Why?
|
Medicare Part B | 1 | 2005 | 116 | 0.060 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2004 | 170 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2016 | 7852 | 0.050 |
Why?
|
Child Health Services | 1 | 2009 | 645 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2007 | 879 | 0.050 |
Why?
|
Anxiety | 3 | 2002 | 4672 | 0.050 |
Why?
|
Pharmacogenetics | 1 | 2006 | 683 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 4055 | 0.050 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2004 | 348 | 0.050 |
Why?
|
Depressive Disorder, Major | 3 | 2004 | 4818 | 0.050 |
Why?
|
Adult | 21 | 2020 | 223646 | 0.050 |
Why?
|
Tendon Transfer | 1 | 2022 | 125 | 0.050 |
Why?
|
Employer Health Costs | 3 | 1995 | 21 | 0.050 |
Why?
|
Heart Rate | 1 | 2012 | 4214 | 0.050 |
Why?
|
Mental Disorders | 2 | 2000 | 6874 | 0.050 |
Why?
|
Oxygen | 1 | 2012 | 4270 | 0.050 |
Why?
|
Sulfonylurea Compounds | 1 | 2022 | 220 | 0.050 |
Why?
|
Rupture | 1 | 2022 | 444 | 0.050 |
Why?
|
Natural Language Processing | 2 | 2020 | 1203 | 0.050 |
Why?
|
Drug Resistance | 2 | 2004 | 1599 | 0.050 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2007 | 617 | 0.050 |
Why?
|
Treatment Refusal | 1 | 2004 | 433 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2005 | 744 | 0.040 |
Why?
|
Health Services Research | 2 | 2004 | 1815 | 0.040 |
Why?
|
Middle Aged | 18 | 2020 | 223492 | 0.040 |
Why?
|
Coronavirus Infections | 1 | 2017 | 3115 | 0.040 |
Why?
|
Managed Care Programs | 2 | 2002 | 939 | 0.040 |
Why?
|
Hospitals, Pediatric | 1 | 2009 | 1876 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2013 | 5349 | 0.040 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2002 | 491 | 0.040 |
Why?
|
Prognosis | 2 | 2020 | 30010 | 0.040 |
Why?
|
Workplace | 3 | 1999 | 873 | 0.040 |
Why?
|
Sertraline | 2 | 2000 | 209 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 12252 | 0.040 |
Why?
|
Legislation, Medical | 1 | 1979 | 99 | 0.040 |
Why?
|
Aged | 12 | 2020 | 171504 | 0.040 |
Why?
|
Comorbidity | 6 | 2004 | 10590 | 0.040 |
Why?
|
Blood Pressure | 1 | 2013 | 8543 | 0.040 |
Why?
|
Chronic Disease | 5 | 2009 | 9384 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2005 | 6514 | 0.040 |
Why?
|
Logistic Models | 3 | 2020 | 13290 | 0.040 |
Why?
|
Medical Records | 1 | 2022 | 1410 | 0.030 |
Why?
|
Multivariate Analysis | 4 | 2006 | 12077 | 0.030 |
Why?
|
Headache | 1 | 2005 | 1263 | 0.030 |
Why?
|
Occupational Diseases | 1 | 2005 | 1457 | 0.030 |
Why?
|
Ventilation | 1 | 2017 | 129 | 0.030 |
Why?
|
Organizational Policy | 1 | 1999 | 435 | 0.030 |
Why?
|
Regression Analysis | 3 | 2002 | 6340 | 0.030 |
Why?
|
Asthma | 3 | 2006 | 6291 | 0.030 |
Why?
|
Models, Economic | 3 | 2007 | 719 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15454 | 0.030 |
Why?
|
Piperazines | 1 | 2007 | 2554 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2003 | 2732 | 0.030 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2019 | 475 | 0.030 |
Why?
|
Cohort Studies | 2 | 2020 | 41754 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2004 | 1596 | 0.030 |
Why?
|
Republic of Korea | 1 | 2017 | 591 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2003 | 1088 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 14164 | 0.030 |
Why?
|
Pyrimidines | 1 | 2007 | 3048 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2020 | 59629 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2011 | 5367 | 0.030 |
Why?
|
Cell Separation | 1 | 2018 | 1728 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 1999 | 1741 | 0.030 |
Why?
|
Young Adult | 2 | 2016 | 60066 | 0.030 |
Why?
|
Pluripotent Stem Cells | 1 | 2019 | 809 | 0.030 |
Why?
|
Migraine Disorders | 1 | 2005 | 1713 | 0.020 |
Why?
|
Task Performance and Analysis | 1 | 1996 | 771 | 0.020 |
Why?
|
Insurance, Health | 1 | 2004 | 2517 | 0.020 |
Why?
|
Universities | 1 | 2016 | 1005 | 0.020 |
Why?
|
Telemedicine | 1 | 2009 | 3109 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2018 | 1667 | 0.020 |
Why?
|
Models, Biological | 1 | 2007 | 9495 | 0.020 |
Why?
|
Environment | 1 | 2017 | 1121 | 0.020 |
Why?
|
Models, Econometric | 2 | 2004 | 215 | 0.020 |
Why?
|
Hypnotics and Sedatives | 1 | 1999 | 1191 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2019 | 1596 | 0.020 |
Why?
|
Sex Factors | 3 | 2000 | 10632 | 0.020 |
Why?
|
Anti-Asthmatic Agents | 2 | 2006 | 577 | 0.020 |
Why?
|
Heart Arrest | 1 | 2020 | 1516 | 0.020 |
Why?
|
Risk | 2 | 2004 | 9613 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2002 | 3620 | 0.020 |
Why?
|
Quality of Life | 2 | 2022 | 13490 | 0.020 |
Why?
|
Multiple Sclerosis | 1 | 2004 | 3250 | 0.020 |
Why?
|
Adolescent | 9 | 2009 | 89169 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2002 | 3231 | 0.020 |
Why?
|
Emergency Medical Services | 1 | 2019 | 1947 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2018 | 1672 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 1999 | 2748 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 8054 | 0.020 |
Why?
|
Bipolar Disorder | 2 | 2002 | 5130 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54926 | 0.020 |
Why?
|
Medicare | 1 | 2005 | 6809 | 0.020 |
Why?
|
Amitriptyline | 1 | 2006 | 112 | 0.020 |
Why?
|
Physicians | 1 | 2004 | 4598 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1996 | 6029 | 0.020 |
Why?
|
Health Status | 1 | 1998 | 4091 | 0.020 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2006 | 139 | 0.020 |
Why?
|
Drug Utilization Review | 1 | 2006 | 248 | 0.020 |
Why?
|
Statistics as Topic | 2 | 2005 | 2357 | 0.010 |
Why?
|
Amines | 1 | 2006 | 280 | 0.010 |
Why?
|
Doxazosin | 1 | 2004 | 18 | 0.010 |
Why?
|
Chicago | 1 | 2005 | 255 | 0.010 |
Why?
|
Episode of Care | 1 | 2005 | 127 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2007 | 640 | 0.010 |
Why?
|
Hypertension | 1 | 2004 | 8616 | 0.010 |
Why?
|
Insurance Claim Reporting | 1 | 2004 | 166 | 0.010 |
Why?
|
Health Planning | 1 | 2004 | 233 | 0.010 |
Why?
|
Age Factors | 1 | 1999 | 18412 | 0.010 |
Why?
|
Treatment Outcome | 3 | 2004 | 65371 | 0.010 |
Why?
|
Hospitalization | 2 | 2020 | 10840 | 0.010 |
Why?
|
Insurance Benefits | 1 | 2004 | 185 | 0.010 |
Why?
|
Educational Status | 2 | 2000 | 2515 | 0.010 |
Why?
|
Adrenergic beta-Agonists | 1 | 2003 | 347 | 0.010 |
Why?
|
Evidence-Based Medicine | 2 | 2004 | 3706 | 0.010 |
Why?
|
Financing, Personal | 1 | 2004 | 310 | 0.010 |
Why?
|
Cost Savings | 1 | 2006 | 904 | 0.010 |
Why?
|
Utilization Review | 1 | 2002 | 381 | 0.010 |
Why?
|
Benzamides | 1 | 2007 | 1379 | 0.010 |
Why?
|
Intention | 1 | 2004 | 347 | 0.010 |
Why?
|
Age of Onset | 2 | 2000 | 3347 | 0.010 |
Why?
|
Combined Modality Therapy | 2 | 2004 | 8542 | 0.010 |
Why?
|
Cardiovascular Agents | 1 | 2006 | 849 | 0.010 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2006 | 1141 | 0.010 |
Why?
|
Cost Allocation | 1 | 1999 | 48 | 0.010 |
Why?
|
Direct Service Costs | 1 | 1999 | 61 | 0.010 |
Why?
|
Infant | 3 | 2009 | 36535 | 0.010 |
Why?
|
Censuses | 1 | 2000 | 198 | 0.010 |
Why?
|
Fee-for-Service Plans | 1 | 2004 | 713 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39348 | 0.010 |
Why?
|
Health Services | 1 | 2004 | 755 | 0.010 |
Why?
|
Drugs, Generic | 1 | 2004 | 455 | 0.010 |
Why?
|
Child, Preschool | 3 | 2009 | 42669 | 0.010 |
Why?
|
Child | 5 | 2009 | 80917 | 0.010 |
Why?
|
Blood Banks | 1 | 1979 | 108 | 0.010 |
Why?
|
Marital Status | 1 | 1999 | 426 | 0.010 |
Why?
|
Ambulatory Care | 2 | 2002 | 2783 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2006 | 1673 | 0.010 |
Why?
|
Treatment Failure | 1 | 2004 | 2661 | 0.010 |
Why?
|
Psychotropic Drugs | 1 | 2002 | 881 | 0.010 |
Why?
|
Prevalence | 3 | 2004 | 15869 | 0.010 |
Why?
|
Pandemics | 1 | 2016 | 8748 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2006 | 1923 | 0.010 |
Why?
|
Hospital Costs | 1 | 2002 | 957 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2009 | 26422 | 0.010 |
Why?
|
Risk Factors | 2 | 2020 | 74944 | 0.010 |
Why?
|
Longitudinal Studies | 2 | 2002 | 14783 | 0.010 |
Why?
|
Fees and Charges | 1 | 1977 | 189 | 0.010 |
Why?
|
Data Collection | 1 | 2005 | 3327 | 0.010 |
Why?
|
Liability, Legal | 1 | 1977 | 209 | 0.010 |
Why?
|
Altruism | 1 | 1977 | 211 | 0.010 |
Why?
|
Psychotherapy | 1 | 2004 | 1654 | 0.010 |
Why?
|
Family Characteristics | 1 | 1999 | 1003 | 0.010 |
Why?
|
Survival Analysis | 1 | 2007 | 10101 | 0.010 |
Why?
|
Economics | 1 | 1993 | 141 | 0.010 |
Why?
|
Employment | 1 | 1999 | 1110 | 0.010 |
Why?
|
Public Policy | 1 | 1977 | 552 | 0.010 |
Why?
|
Prescription Fees | 1 | 1993 | 153 | 0.010 |
Why?
|
Patient Compliance | 1 | 2002 | 2697 | 0.010 |
Why?
|
Income | 1 | 2000 | 1878 | 0.010 |
Why?
|
Massachusetts | 1 | 2004 | 8890 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2004 | 12543 | 0.010 |
Why?
|
Pain Measurement | 1 | 1999 | 3583 | 0.010 |
Why?
|
Health Policy | 1 | 1979 | 2698 | 0.000 |
Why?
|
Double-Blind Method | 1 | 2000 | 12465 | 0.000 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1993 | 2204 | 0.000 |
Why?
|
Suicide | 1 | 1993 | 1606 | 0.000 |
Why?
|
Time Factors | 1 | 2004 | 40218 | 0.000 |
Why?
|
Arthritis, Rheumatoid | 1 | 1995 | 3781 | 0.000 |
Why?
|
Coronary Disease | 1 | 1993 | 5919 | 0.000 |
Why?
|